{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T13:27:39Z","timestamp":1786973259201,"version":"build-2736575974"},"reference-count":32,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ijgc.2025.102677","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T07:22:06Z","timestamp":1759216926000},"page":"102677","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploratory evaluation of the somatic and immunologic landscape of primary and metastatic cervical cancer to better inform future clinical trial development"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6842-1424","authenticated-orcid":false,"given":"Victoria","family":"Cerda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bobbie J.","family":"Rimel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Mercer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7930-4610","authenticated-orcid":false,"given":"Michael A.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Shieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma L.","family":"Barber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Summer","family":"Dewdney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5646-343X","authenticated-orcid":false,"given":"Ritu","family":"Salani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana I.","family":"Tergas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Tucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Kamrava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijgc.2025.102677_bib1","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102677_bib3","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/jamaoncol.2023.5410","article-title":"Pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer: subgroup analyses from the KEYNOTE-826 randomized clinical trial","volume":"10","author":"Tewari","year":"2024","journal-title":"JAMA Oncol"},{"issue":"10421","key":"10.1016\/j.ijgc.2025.102677_bib4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(23)02405-4","article-title":"Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial","volume":"403","author":"Oaknin","year":"2024","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.ijgc.2025.102677_bib5","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S1470-2045(23)00329-7","article-title":"First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial","volume":"24","author":"\u00d6zg\u00fcro\u011flu","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijgc.2025.102677_bib6","article-title":"Pattern of disease and response to pembrolizumab in recurrent cervical cancer","volume":"37","author":"Miller","year":"2021","journal-title":"Gynecol Oncol Rep"},{"issue":"9","key":"10.1016\/j.ijgc.2025.102677_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004884","article-title":"Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites","volume":"10","author":"Conway","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"11","key":"10.1016\/j.ijgc.2025.102677_bib8","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/s41587-019-0259-z","article-title":"Integrated genomic profiling expands clinical options for patients with cancer","volume":"37","author":"Beaubier","year":"2019","journal-title":"Nat Biotechnol"},{"issue":"24","key":"10.1016\/j.ijgc.2025.102677_bib9","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.18632\/oncotarget.26797","article-title":"Clinical validation of the tempus xT next-generation targeted oncology sequencing assay","volume":"10","author":"Beaubier","year":"2019","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102677_bib10","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s40291-023-00650-5","article-title":"Validation of a transcriptome-based assay for classifying cancers of unknown primary origin","volume":"27","author":"Michuda","year":"2023","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.ijgc.2025.102677_bib11","unstructured":"Tempus xR validation. Tempus AI, Inc. Accessed October 8th, 2025. https:\/\/www.tempus.com\/wp-content\/uploads\/2023\/06\/Tempus-xR_Validation.pdf."},{"key":"10.1016\/j.ijgc.2025.102677_bib12","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nature21386","article-title":"Integrated genomic and molecular characterization of cervical cancer","volume":"543","year":"2017","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102677_bib13","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jtho.2019.12.109","article-title":"Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies","volume":"15","author":"Chung","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"20","key":"10.1016\/j.ijgc.2025.102677_bib14","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102677_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"issue":"44","key":"10.1016\/j.ijgc.2025.102677_bib16","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000035757","article-title":"Expression of PD-1\/PD-L1 in peripheral blood and tumor tissues of patients with classical Hodgkin\u2019s lymphoma","volume":"102","author":"Feng","year":"2023","journal-title":"Medicine (Baltimore)"},{"issue":"13","key":"10.1016\/j.ijgc.2025.102677_bib17","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.23.02479","article-title":"Predicted value of PD-L1 for patients with cervical cancer treated with pembrolizumab","volume":"42","author":"Luo","year":"2024","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.ijgc.2025.102677_bib18","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102677_bib19","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1158\/1078-0432.CCR-15-1678","article-title":"Microsatellite instability as a biomarker for PD-1 blockade","volume":"22","author":"Dudley","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"6349","key":"10.1016\/j.ijgc.2025.102677_bib20","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102677_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22041807","article-title":"Targeting the PD-1 axis with pembrolizumab for recurrent or metastatic cancer of the uterine cervix: a brief update","volume":"22","author":"Verhoeven","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.ijgc.2025.102677_bib22","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41571-024-00932-9","article-title":"Tumour mutational burden: clinical utility, challenges and emerging improvements","volume":"21","author":"Budczies","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"22","key":"10.1016\/j.ijgc.2025.102677_bib23","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1158\/1078-0432.CCR-23-1078","article-title":"Assessing the genomic landscape of cervical cancers: clinical opportunities and therapeutic targets","volume":"29","author":"Friedman","year":"2023","journal-title":"Clin Cancer Res."},{"issue":"13","key":"10.1016\/j.ijgc.2025.102677_bib24","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1158\/1078-0432.CCR-19-3211","article-title":"B cells improve overall survival in HPV-associated squamous cell carcinomas and are activated by radiation and PD-1 blockade","volume":"26","author":"Kim","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.ijgc.2025.102677_bib25","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41568-022-00466-1","article-title":"Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities","volume":"22","author":"Laumont","year":"2022","journal-title":"Nat Rev Cancer"},{"issue":"7791","key":"10.1016\/j.ijgc.2025.102677_bib26","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","article-title":"B cells are associated with survival and immunotherapy response in sarcoma","volume":"577","author":"Petitprez","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ijgc.2025.102677_bib27","article-title":"Liver metastasis and resistance to immunotherapy in microsatellite stable colorectal cancer. A literature review","volume":"18","author":"Aruquipa","year":"2024","journal-title":"Ecancermedicalscience"},{"issue":"5","key":"10.1016\/j.ijgc.2025.102677_bib28","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1158\/2326-6066.CIR-16-0325","article-title":"Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC","volume":"5","author":"Tumeh","year":"2017","journal-title":"Cancer Immunol Res"},{"issue":"9","key":"10.1016\/j.ijgc.2025.102677_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111295","article-title":"Tumor-infiltrated activated B cells suppress liver metastasis of colorectal cancers","volume":"40","author":"Xu","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.ijgc.2025.102677_bib30","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1016\/S0090-8258(22)01369-5","article-title":"Alpelisb for the treatment of PIK3CA-mutated, recurrent\/advanced cervical cancer (142)","volume":"166","author":"Bogani","year":"2022","journal-title":"Gynecol Oncol"},{"issue":"17","key":"10.1016\/j.ijgc.2025.102677_bib31","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1056\/NEJMoa2404625","article-title":"Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer","volume":"391","author":"Turner","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijgc.2025.102677_bib32","series-title":"Study of chemotherapy plus Ipatasertib for people with solid tumors with PTEN\/AKT mutations, A ComboMATCH treatment trial","year":"2016"},{"issue":"12","key":"10.1016\/j.ijgc.2025.102677_bib33","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2309902121","article-title":"Epidermal growth factor receptor (EGFR) is a target of the tumor-suppressor E3 ligase FBXW7","volume":"121","author":"Boretto","year":"2024","journal-title":"Proc Natl Acad Sci U S A."}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25017979?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25017979?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:58:25Z","timestamp":1786971505000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X25017979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1048891X25017979"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.102677","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploratory evaluation of the somatic and immunologic landscape of primary and metastatic cervical cancer to better inform future clinical trial development","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.102677","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102677"}}